Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Stroke Cerebrovasc Dis ; 31(1): 106187, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34749297

RESUMO

OBJECTIVE: Patterns of cytokine levels and their association with stroke severity, infarct size, and muscle strength are obscure. We aimed to analyze the immune mediators linked to T helper (Th)1, Th2, Th17, and regulatory T cell patterns and their association with stroke severity, infarct size, and muscle strength. MATERIALS AND METHODS: We included patients with acute stroke (n = 15) and healthy non-disabled individuals (n = 20) aged > 18 years. The dependent variables were stroke severity according to the National Institute of Health Stroke Scale (NIHSS), infarct size on computed tomography, handgrip strength by dynamometry, and global muscle strength according to the Medical Research Council (MRC) scale. The independent variables were the circulating cytokine levels. The cytokine levels were compared between the groups, and correlations between the clinical data were verified. RESULTS: The stroke group had higher interleukin (IL)-6 (p < 0.0001) and IL-10 (p < 0.0001) levels, but lower tumor necrosis factor (TNF)-α (p = 0.036) levels than the control group. IL-10 and soluble tumor necrosis factor receptor (sTNF-RII) levels were correlated with each other (r = 0.533; p = 0.042) and infarct size (r = 0.653; p = 0.033 and r = 0.689; p = 0.018, respectively). MRC scores were positively and negatively correlated with handgrip strength of the affected side (r = 0.78; p = 0.001) and NIHSS scores (r = -0.87; p < 0.0001), respectively. CONCLUSIONS: Plasma levels of some cytokines were associated with changes in the acute phase of stroke, and IL-10 and sTNF-RII levels are potential biomarkers of infarct size.


Assuntos
Citocinas , Infarto , Força Muscular , Acidente Vascular Cerebral , Adulto , Citocinas/sangue , Força da Mão/fisiologia , Humanos , Infarto/epidemiologia , Interleucina-10/sangue , Interleucina-6/sangue , Força Muscular/fisiologia , Gravidade do Paciente , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/fisiopatologia , Fator de Necrose Tumoral alfa/sangue
2.
Mediators Inflamm ; 2017: 7151285, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28321152

RESUMO

Pemphigus vulgaris (PV) is an autoimmune disease characterized by the presence of IgG autoantibodies against desmoglein-3. Despite the variety of findings, the chemokine and cytokine profiles that characterize the immune response in the disease are still poorly explored. Thus, 20 PV patients and 20 controls were grouped according to gender, ethnicity, place of residence, and clinical parameters of the disease. Then, the levels of chemokines and of Th1/Th2/Th17/Treg/Th9/Th22-related cytokines were assessed in the serum. PV patients had higher levels of inflammatory Th1/Th17 cytokines (IFN-γ, IL-17, and IL-23), as well as higher levels of CXCL8 and reduced levels of Th1/Th2-related chemokines (IP-10 and CCL11). However, no differences in the levels of IL-2, IL-6, TNF-α, IL-1ß, IL-4, IL-9, IL-12, TGF-ß, IL-33, MCP-1, RANTES, and MIP-1α were found between PV patients and their control counterparts. Furthermore, PV patients with skin lesions had higher serum levels of IL-6 and CXCL8 when compared to PV patients without lesions. Taken together, our findings describe the role of cytokines and chemokines associated with Th1/Th17 immune response in PV patients. Finally, these data are important for better understanding of the immune aspects that control disease outcome, and they may also provide important information about why patients develop autoantibodies against desmogleins.


Assuntos
Quimiocinas/metabolismo , Citocinas/metabolismo , Pênfigo/patologia , Células Th1/metabolismo , Células Th17/metabolismo , Adulto , Quimiocina CCL3/metabolismo , Quimiocina CCL5/metabolismo , Feminino , Humanos , Interleucina-2/metabolismo , Interleucina-23/metabolismo , Interleucina-6/metabolismo , Interleucina-8/metabolismo , Masculino , Pessoa de Meia-Idade , Linfócitos T Reguladores/metabolismo , Células Th2/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Adulto Jovem
3.
Rev Bras Reumatol Engl Ed ; 56(6): 497-503, 2016.
Artigo em Inglês, Português | MEDLINE | ID: mdl-27914596

RESUMO

OBJECTIVE: To characterize the inflammatory profiles of patients with systemic lupus erythematosus receiving standard treatment compared to healthy controls. PATIENTS AND METHODS: Peripheral venous blood was collected from systemic lupus erythematosus patients (n=14) and controls (n=18) at enrollment. Blood samples were used for quantification, by flow cytometry, of CD11b (integrin) and Chemokine receptor CXCR2 expression surface antigen in neutrophils and lymphocytes, while cytokines were assayed in serum samples. Purified neutrophils were assayed by their ability to phagocytize human plasma-opsonized zymosan. RESULTS: Patients had a median (interquartile range) disease activity index of 1.0 (0-2.0) characteristic of patients in remission. Interleukin-6 and interleukin-10 serum concentrations were significantly higher in the patient group compared to controls and the phagocytic index of circulating neutrophils was significantly reduced in patients compared to controls. The levels of interleukin-2, interleukin-5, interleukin-8 and tumor necrosis factor alpha did not significantly differ between patients and controls. Flow cytometric analysis revealed that the integrin expression levels were reduced in lymphocytes (but not in neutrophils) obtained from systemic lupus erythematosus patients, while surface expression of the chemokine receptor 2 was similar in both neutrophils and lymphocytes. CONCLUSION: Systemic lupus erythematosus patients receiving standard treatment presented with elevated systemic levels of interleukin-6 and interleukin-10, reduced neutrophil phagocytic capacity, and reduced lymphocyte expression of integrin even when symptoms were in remission. These alterations to innate immune components may put these individuals at a greater risk for acquiring infections.


Assuntos
Citocinas/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Linfócitos/imunologia , Neutrófilos/imunologia , Biomarcadores/sangue , Estudos de Casos e Controles , Humanos , Interleucina-6
4.
Rev. bras. reumatol ; 56(6): 497-503, Nov.-Dec. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-830071

RESUMO

ABSTRACT Objective: To characterize the inflammatory profiles of patients with systemic lupus erythematosus receiving standard treatment compared to healthy controls. Patients and methods: Peripheral venous blood was collected from systemic lupus erythematosus patients (n = 14) and controls (n = 18) at enrollment. Blood samples were used for quantification, by flow cytometry, of CD11b (integrin) and Chemokine receptor CXCR2 expression surface antigen in neutrophils and lymphocytes, while cytokines were assayed in serum samples. Purified neutrophils were assayed by their ability to phagocytize human plasma-opsonized zymosan. Results: Patients had a median (interquartile range) disease activity index of 1.0 (0-2.0) characteristic of patients in remission. Interleukin-6 and interleukin-10 serum concentrations were significantly higher in the patient group compared to controls and the phagocytic index of circulating neutrophils was significantly reduced in patients compared to controls. The levels of interleukin-2, interleukin-5, interleukin-8 and tumor necrosis factor alpha did not significantly differ between patients and controls. Flow cytometric analysis revealed that the integrin expression levels were reduced in lymphocytes (but not in neutrophils) obtained from systemic lupus erythematosus patients, while surface expression of the chemokine receptor 2 was similar in both neutrophils and lymphocytes. Conclusion: Systemic lupus erythematosus patients receiving standard treatment presented with elevated systemic levels of interleukin-6 and interleukin-10, reduced neutrophil phagocytic capacity, and reduced lymphocyte expression of integrin even when symptoms were in remission. These alterations to innate immune components may put these individuals at a greater risk for acquiring infections.


RESUMO Objetivo: Caracterizar os perfis inflamatórios de pacientes com lúpus eritematoso sistêmico (LES) que recebiam o tratamento padrão em comparação com controles saudáveis. Pacientes e métodos: Coletou-se o sangue venoso periférico de pacientes com LES (n = 14) e controles (n = 18) no momento da entrada no estudo. As amostras de sangue foram usadas para quantificação, por citometria de fluxo, da expressão dos antígenos de superfície CD11b (integrina) e CXCR2 em neutrófilos e linfócitos, enquanto as citocinas foram avaliadas em amostras de soro. Avaliou-se a capacidade dos neutrófilos purificados de fagocitar zimosan opsonizado com plasma humano. Resultados: Os pacientes apresentavam uma pontuação mediana (intervalo interquartil) no Sledai de 1 (0-2), característica de pacientes em remissão. As concentrações séricas de IL-6 e IL-10 foram significativamente maiores no grupo de pacientes em comparação com os controles; o índice de fagocitose de neutrófilos circulantes estava significativamente reduzido nos pacientes em comparação com os controles. Os níveis de IL-2, IL-5, IL-8 e TNF-α não diferiram significativamente entre pacientes e controles. A análise da citometria de fluxo revelou que os níveis de expressão de CD11b estavam reduzidos nos linfócitos (mas não nos neutrófilos) obtidos de pacientes com LES, enquanto a expressão do receptor de superfície CXCR2 foi semelhante em neutrófilos e linfócitos. Conclusão: Os pacientes com LES que recebiam tratamento padrão apresentaram níveis sistêmicos elevados de IL-6 e IL-10, redução na capacidade fagocítica dos neutrófilos e redução da expressão de CD11b em linfócitos, mesmo quando os sintomas estavam em remissão. Essas alterações nos componentes da imunidade inata podem colocar esses indivíduos em maior risco de adquirir infecções.


Assuntos
Humanos , Linfócitos/imunologia , Citocinas/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Neutrófilos , Biomarcadores/sangue , Estudos de Casos e Controles , Interleucina-6
5.
Rev. Soc. Bras. Med. Trop ; 43(5): 580-583, set.-out. 2010. ilus
Artigo em Português | LILACS | ID: lil-564299

RESUMO

INTRODUÇÃO: O pênfigo é uma doença autoimune, caracterizada por vésico-bolhas cuja manifestações clínicas crônicas geram alterações na qualidade de vida. Existem relatos de pênfigo em vários continentes; porém ocorre predominantemente na região centro-norte da América do Sul. No Brasil, a doença predomina nos estados do Centro-Oeste e Sudeste. Objetivou-se avaliar o perfil e a qualidade de vida de pacientes com pênfigo em uma cidade brasileira, para intervenção fisioterapêutica. MÉTODOS: Foram analisados 15 prontuários de pacientes institucionalizados; contudo, 7 voluntários passaram por entrevista inicial e final por meio do questionário de qualidade de vida SF-36. Entremeio a coleta de dados, foram aplicados exercícios fisioterapêuticos durante o período de 4 meses. Após o período pré-determinado os dados foram comparados e analisados de forma quantitativa por meio do Med Calc E e teste T the student. RESULTADOS: Os 15 pacientes em tratamento tinham idade média de 40 anos; 53,3 por cento eram melanoderma; o gênero masculino correspondia a 80 por cento; 60 por cento apresentam contato com zona rural e 80 por cento são de origem da região sudeste. Os 7 pacientes que participaram da intervenção tenderam melhorar os domínios avaliados pelo SF-36 com exceção da vitalidade e aspectos sociais. CONCLUSÕES: O perfil da população deste hospital tem correlação com a literatura pesquisada. De acordo com o SF-36, houve melhora geral da qualidade de vida dos pacientes que aderiram às atividades propostas. Essa pesquisa sugere que a intervenção fisioterapêutica promove diferentes benefícios para os pacientes com pênfigo.


INTRODUCTION: Pemphigus is an autoimmune disease characterized by bullae, in which its chronicity and clinical manifestations generate alterations in the quality of life. In Brazil, the disease prevails in the states of the Midwest and Southeast. The study aimed to evaluate the profile and quality of life of patients with pemphigus in a Brazilian city, for the purposes of physiotherapeutic intervention. METHODS: The medical records of 15 institutionalized patients were analyzed, though only 7 volunteers underwent the initial and final interviews using the quality of life questionnaire SF-36. Between data collections, physical therapy exercises were applied over a four-month period. After this predetermined period the data were compared and analyzed quantitatively using the Med Calc E and the Student t test. RESULTS: The 15 patients in treatment had a mean age of 40 years-old; 53.3 percent were melanoderm; 80 percent were men; 60 percent had contact with rural areas and 80 percent were from the southern region. The 7 patients who participated in the intervention showed a tendency for improvement in the areas assessed by the SF-36, except for vitality and social aspects. CONCLUSIONS: The profile of the population of this hospital is in agreement with the literature. According to the SF-36 collected before and after the physical therapy intervention, general improvement in the quality of life of these patients was verified. This research suggests that physiotherapeutic intervention promotes diverse benefits for patients with pemphigus.


Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Terapia por Exercício/psicologia , Pênfigo/psicologia , Qualidade de Vida/psicologia , Terapia por Exercício/métodos , Pênfigo/reabilitação , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA